Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 2;12:9198. doi: 10.1038/s41598-022-12727-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

IgG profiles in response to trimerized influenza virus VN04 H5 vaccine formulated with different TLR agonists, with or without squalene oil-in-water emulsion (AddaVax). Antibody profiles were determined by probing immune plasma (d28-post vaccination) against HA protein microarray (Supplementary Table S1). Antigens (horizontal axis) are full-length (HA0) HA variants ranked within subtype H1-H18 by overall average of whole study population. Magnitude of response (vertical axis) are geometric means of each vaccine group (N = 4 mice). Breadth of response is summarized in Table 2. CpG cytosine-guanine oligo deoxynucleotide, AddaVax; MPLA monophosphoryl lipid A; PID pyrimido-indole derivative; TLRa TLR agonist. Kruskal Wallis Dunn's multiple comparison between + and − AddaVax are indicated for H1 and H5; ****P < 0.0001; ***P ≤ 0.001; **P ≤ 0.01; *P < 0.05.